Rheumatology Research

An atypical presentation of axial spondyloarthritis with severe acute low back pain: A case report

Document Type : Case Report

Authors

1 Department of Internal Medicine, Shahid Modarres Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran

2 School of medicine, Tehran University of Medical Science, Tehran, Iran Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran

3 School of medicine, Tehran University of Medical Science, Tehran, Iran

4 Department of Rheumatology,Imam khomeini hospital,Tehran university of medical sciences tehran , Iran

10.32592/RR.2024.9.2.117

Abstract

Axial spondyloarthritis (axSpA) represents a chronic inflammatory condition primarily impacting axial joints, characterized by sacroiliitis and spondylitis. In axSpA patients, low back pain (LBP) typically assumes a chronic and inflammatory nature, where diagnostic delays can precipitate disability. However, atypical axSpA presentations pose challenges for early diagnosis and management. In the current study, we detail the case of a 39-year-old male presenting with acute, severe LBP and bilateral sacroiliitis. Initial treatment with non-steroidal anti-inflammatory drugs (NSAIDs), the standard first-line therapy, was discontinued due to severe gastrointestinal bleeding. Following a bone biopsy that excluded alternative etiologies, axSpA was confirmed based on diagnostic criteria. Elevated inflammatory markers, contraindications to NSAIDs, and magnetic resonance imaging findings prompted the initiation of anti-tumor necrosis factor (TNF) therapy. Remarkably, a marked improvement was observed in less than six weeks post anti-TNF therapy commencement. This case underscores the significance of recognizing atypical axSpA presentations and underscores the potential for swift and robust responses to anti-TNF agents. Optimal patient outcomes hinge upon effective disease pattern recognition and treatment selection.

Keywords

Main Subjects

References
  1. Leone A, Marino M, Dell'Atti C, Zecchi V, Magarelli N, Colosimo C. Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int 2016; 36(10):1335-46. doi: 10. 1007/s00296-016-3524-1.
  2. Zhang N, Li H, Xu ZK, Chen WS, Chen QX, Li FC. Computer simulation of two-level pedicle subtraction osteotomy for severe thoracolumbar kyphosis in ankylosing spondylitis. Indian J Orthop 2017; 51(6):666-71. doi: 10.4103/ortho. IJOrtho_222_16.
  3. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults-- United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50(7):120-5.
  4. Kuritzky L, Samraj GP. Nonsteroidal anti[1]inflammatory drugs in the treatment of low back pain. J Pain Res 2012; 5:579-90. doi: 10. 2147/JPR.S6775.
  5. Zheng GQ, Song K, Zhang YG, Wang Y, Huang P, Zhang XS, et al. Two-level spinal osteotomy for severe thoracolumbar kyphosis in ankylosing spondylitis. Experience with 48 patients. Spine (Phila Pa 1976) 2014; 39(13):1055-8. doi: 10.1097/BRS .000000000 0000346.
  6. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70(1):25-31. doi: 10.1136/ard.2010.135889.
  7. Gran JT, Ostensen M, Husby G. A clinical comparison between males and females with ankylosing spondylitis. J Rheumatol 1985; 12 (1):126-9.
  8. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993; 20(11):1900- 4.
  9. Luo F, Zhao Z, Zhang J, Leng J. Comparison of HLA-B*27 subtypes between Chinese patients with ankylosing spondylitis and non[1]ankylosing spondylitis carriers. J Int Med Res. 2019; 47(7):3171-8.
  10. Sykes MP, Doll H, Sengupta R, Gaffney K. Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? Rheumatology (Oxford) 2015; 54(12):2283-4. doi: 10.1093/ rheumatology/kev288.
  11. Bashir MT, Iversen L, Burton C. Clinical features in primary care electronic records before diagnosis of ankylosing spondylitis: a nested case-control study. BMC Fam Pract 2020; 21(1):78. doi: 10.1186/s12875-020-011 49-2.
  12. Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, et al. Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC Musculoskelet Disord 2018; 19(1):317. doi: 10. 1186/s12891-018-2211-7.
  13. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52(4):1000-8. doi: 10.1002/art.20990.
  14. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68(12): 1811-8. doi: 10.1136/ard.2008.100826.
  15. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondylo arthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018; 77(1):3-17. doi: 10.1136/annrheumdis-2017- 211734.
  16. Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, et al. The ASAS[1]OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum 2021; 51(6):1342-9. doi: 10.1016/j.semarthrit. 2021.07.021.
  17. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70(6):896-904. doi: 10.1136/ard.2011. 151027.
  18. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33(9):1805-12.
  19. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondylo[1] Ann Rheum Dis 2011; 70 (2):249-51. doi: 10.1136/ard.2010.133488.
  20. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67(3):323-9. doi: 10. 1136/ard.2007.075309.
  21. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52(4):1205-15. doi: 10.1002/art.20985.
  22. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71(10):1616-22. doi: 10. 1136/annrheumdis-2011-201252.
  23. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36(4):801-8. doi: 10. 3899/ jrheum.081048.
  24. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; 64(11):1557-62. doi: 10. 1136/ard.2004.035105.
  25. Inman RD, Davis JC, Jr., Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double[1]blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58(11):3402-12. doi: 10.1002/art.23969.
  26. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2):582- 91. doi: 10.1002/art.20852.
  27. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54(7):2136-46. doi: 10.1002/art.21913.
  28. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58(7): 1981-91. doi: 10.1002/art.23606.
  29. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker[1]naive patients with active ankylosing spondyl[1]itis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62(5): 1290-7. doi: 10.1002/art.27383.
  30. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Ghogomu ET, et al. TNF‐alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; (4):CD005468. doi: 10.1002/14651858.
  31. Macfarlane GJ, Pathan E, Jones GT, Dean LE. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford) 2020; 59(9):2481-90. doi: 10.1093/rheumatology/kez657
Rheumatology Research
Volume 9, Issue 2
April 2024
Pages 117-123
Files
Share
How to cite
Statistics